TKIs have significantly prolonged the PFS and OS in EGFR-mutant NSCLC patients, with the second- and third-generation TKIs demonstrating enhanced efficacies (Cooper et al., 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.